The management of CNS (CNS) metastases in NSCLC (NSCLC) has emerged as a significant breakthrough with the novel TKI (TKI), osimertinib.This article delves into the effectiveness of osimertinib in managing CNS (CNS) metastases, as well as explores its implications for patients with NSCLC (NSCLC).Osimertinib targets the EGFR (EGFR) mutation, a common genetic mutation found in NSCLC (NSCLC).By blocking the EGFR pathway, the cancer cell proliferation and metastasis are aided in prevention by osimertinib.The effectiveness of osimertinib in treating CNS (CNS) metastases in NSCLC (NSCLC) has been demonstrated by numerous research…
